Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NEETA SOMAIAH and VINOD RAVI.
NEETA SOMAIAH
Connection Strength
2.815
VINOD RAVI
  1. Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel). 2024 Apr 27; 16(9).
    View in: PubMed
    Score: 0.240
  2. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).
    View in: PubMed
    Score: 0.237
  3. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
    View in: PubMed
    Score: 0.237
  4. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
    View in: PubMed
    Score: 0.215
  5. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
    View in: PubMed
    Score: 0.213
  6. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391.
    View in: PubMed
    Score: 0.212
  7. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020; 2020:8363986.
    View in: PubMed
    Score: 0.183
  8. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
    View in: PubMed
    Score: 0.158
  9. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma. 2017; 2017:7495914.
    View in: PubMed
    Score: 0.152
  10. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep. 2017 08 25; 7(1):9519.
    View in: PubMed
    Score: 0.151
  11. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma? Am J Clin Oncol. 2024 Sep 03.
    View in: PubMed
    Score: 0.061
  12. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors. 2024; 16:20363613241271669.
    View in: PubMed
    Score: 0.061
  13. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel). 2024 May 01; 16(9).
    View in: PubMed
    Score: 0.060
  14. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
    View in: PubMed
    Score: 0.056
  15. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
    View in: PubMed
    Score: 0.055
  16. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
    View in: PubMed
    Score: 0.054
  17. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 09 15; 28(18):4092-4104.
    View in: PubMed
    Score: 0.054
  18. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522.
    View in: PubMed
    Score: 0.053
  19. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022 06 15; 13(1):3406.
    View in: PubMed
    Score: 0.053
  20. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.
    View in: PubMed
    Score: 0.048
  21. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
    View in: PubMed
    Score: 0.043
  22. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
    View in: PubMed
    Score: 0.042
  23. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963.
    View in: PubMed
    Score: 0.038
  24. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
    View in: PubMed
    Score: 0.037
  25. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Mol Cancer Ther. 2017 09; 16(9):1751-1764.
    View in: PubMed
    Score: 0.037
  26. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
    View in: PubMed
    Score: 0.037
  27. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014 Mar 15; 74(6):1645-50.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.